Gene Therapy Net – News, Conferences, Vectors, Literature …

Posted on: 18 July 2018, source: ArthrogenArthrogen, a clinical stage gene therapy company together with the Centre for Human Drug Research (CHDR), a Leiden based independent clinical research organization, announced that the first three arthritis patients have been enrolled in a phase Ib gene therapy trial for treatment of arthritis with ART-I02. ART-I02 is an adeno-associated virus (AAV5) vector encoding the human IFN- gene under control of an inflammation-responsive promoter. ART-I02 is designed to produce the anti-inflammatory protein IFN- in the synovial cells in the joint. The aim is to achieve a sustained clinical remission with a single treatment. This current clinical phase Ib trial, evaluates the safety, tolerability, pharmacokinetics, immunogenicity and anti-inflammatory activity of ART-I02 treatment in patients with rheumatoid arthritis (RA) or osteoarthritis (OA). In total 12 patients with RA or OA in their hand joints will be included. Parallel to this study, a similar phase Ib trial has started in Canada treating 15 patients with RA in their wrist.

Go here to read the rest:

Gene Therapy Net – News, Conferences, Vectors, Literature …

Related Post

Comments are closed.